You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
IGF OT IGF SBIR PHASE I TOPIC SYSTEMIC TARGETED RADIONUCLIDE THERAPY FOR CANCER TREATMENT PERIOD OF PERFORMANCE
SBC: Icagen, Inc. Topic: NCINot Available
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
IGF OT IGF "LIGAND MAGNETO KIT FOR FAST MODULARBACTERIA COLLECTION"
SBC: LUNA INNOVATIONS INCORPORATED Topic: NIAIDNot Available
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
IGF OT IGF INHALED CLOFAZIMINE POWDER AS NOVEL TREATMENT FOR MDR TB FORMULATION AND PRECLINICAL EVALUATION
SBC: Northbound Therapeutics, Inc. Topic: NIAIDNot Available
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
IGF OT IGF A MAGNETIC MICROPARTICLE KIT FOR CELL REMOVAL FROM BLOOD
SBC: LUNA INNOVATIONS INCORPORATED Topic: NIAIDNot Available
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
IGF OT IGF Circulating nucleic acid based nanowell label free array technology in cancer
SBC: DETROIT R & D, INC. Topic: NCINot Available
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
High-specificity affinity reagents for the detection of glycan sialylation
SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC Topic: 300DESCRIPTION provided by applicant Glycans have several distinct properties that make their development as disease biomarkers appealing Firstly their location on cell surfaces makes them the first point of contact for cellular interactions and thus they are crucial in the control of normal metabolic processes and conversely they function as pathogen adhesion receptors Secondly specific gl ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of Isotopically Labeled Glycoproteins for use as Internal Standards
SBC: GLYCOSCIENTIFIC, L.L.C. Topic: 300DESCRIPTION provided by applicant The ability to accurately quantitate the glycan chains attached to glycoproteins has wide ranging implications Numerous studies over the past years have demonstrated that abnormal glycosylation occurs in virtually all types of human cancers and demonstrate the potential of using glycan markers in either a diagnostic or a prognostic manner The glycosylatio ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
TruEnamel: A dental product that treats, protects, desensitizes and whitens teeth
SBC: TruEnamel, LLC Topic: NIDCRDESCRIPTION provided by applicant Dentin hypersensitivity is a painful condition affecting from of the population It is caused by the movement of fluid in the dentinal tubules and can be eliminated by occluding these patent tubules Tooth whitening is a $ billion business in America and is predicted to grow both here and abroad In this grant we propose a treatment for dentin hypers ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Manufacturing pathogen inactivated platelet lysate to treat corneal inflammation
SBC: Cambium Medical Technologies LLC Topic: NDESCRIPTION provided by applicant Ocular graft versus host disease O GVHD is a particularly severe and debilitating complication of allogeneic hematopoietic stem cell transplantation HSCT O GVHD develops in of patients with chronic GVHD Currently Restasis cyclosporine A is the only FDA approved prescription topical medication to treat O GVHD In Restasis had sales o ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
PDE4B Inhibitors for Treating Brain Injury
SBC: Tetra Discovery Partners, Inc. Topic: 106DESCRIPTION provided by applicant This proposal will develop a new small molecule drug to be advanced into human clinical trials in the chronic post TBI patient who still has chronic cognitive impairments months to years after the initial TBI According to the Centers for Disease Control approximately million Americans suffer from post TBI cognitive impairments This includes people sustai ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
